Oslo, 22 September 2025: Reference is made to the stock exchange announcement published by Navamedic ASA (the “Company“) earlier today, 22 September 2025, regarding the commencement of the subscription period in the partly underwritten rights issue of up to 6,046,511 new shares in the Company, at a subscription price of NOK 21.50 per share (the “Rights Issue“). As part of this process, tradable subscription rights have been allocated to certain primary insiders, and certain close associates of primary insiders, of the Company:

Soleglad Invest AS, a company closely associated with Kathrine Elisabeth Gamborg Andreassen, CEO of the Company, has on 22 September 2025 received 264,165 subscription rights in the Company with no price payable.

Lars Hjarrand, CFO of the Company, has on 22 September 2025 received 121,829 subscription rights in the Company with no price payable.

Jurs AS, a company close associated with Morten Jurs, member of the Board of Directors of the company has on 22 September 2025 received 7,851 subscription rights in the Company with no price payable.

Astrid T. Bratvedt, Chief Scientific Officer of the Company, has on 22 September 2025 received 684 subscription rights in the Company with no price payable.

Tranbergkollen Invest AS, a company closely associated with, Astrid T. Bratvedt, Chief Scientific Officer of the Company, has on 22 September 2025 received 205,398 subscription rights in the Company with no price payable.

Ole Henrik Eriksen, Chief Business Development Officer of the Company, has on 22 September 2025 received 25,674 subscription rights in the Company with no price payable.

Leikerane AS, a company closely associated with Ole Henrik Eriksen, Chief Business Development Officer of the Company, has on 22 September 2025 received 171,165 subscription rights in the Company with no price payable.

Karianne Femtehjell Olsen, Commercial Director CHC & Nutrition of the Company, has on 22 September 2025 received 9,508 subscription rights in the Company with no price payable.

Alexander Lidmejer, COO of the Company, has on 22 September 2025 received 22,981 subscription rights in the Company with no price payable.

Philip Slätis, Commercial Director RX & International, has on 22 September 2025 received 3,423 subscription rights in the Company with no price payable.

Jostein Davidsen, Chairman of the Board of the Company, has on 22 September 2025 received 17,116 subscription rights in the Company with no price payable.

Åsa Kornfeldt, member of the Board of Directors of the Company, has on 22 September 2025 received 1,362 subscription rights in the Company with no price payable.

Edmèe Steenken, member of the Board of Directors of the Company, has on 22 September 2025 received 3,423 subscription rights in the Company with no price payable.

Rune Wahl, member of the Board of Directors of the Company, has on 22 September 2025 received 20,539 subscription rights in the Company with no price payable.

Please see the attached notifications of trade for further information regarding the primary insiders’ and their close associates’ receipt of tradable subscription rights in the Rights Issue.

This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.